KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study.

Dietger Niederwieser, Dirk Hasenclever, Wolfgang E Berdel, Bart J Biemond, Haifa Al-Ali, Yves Chalandon, Michel Van Gelder, Christian Junghanß, Gösta Gahrton, Mathias Hänel, Rüdiger Hehlmann, Thomas Heinicke, Andreas Hochhaus, Simona Iacobelli, Rien van Marwijk Kooy, Nicolaus Kröger, Jeroen Janssen, Madlen Jentzsch, Frank Breywisch, Mohamad Mohty, Stavroula Masouridi-Levrat, Gert Ossenkoppele, Jacob Passweg, Wolfram Pönisch, Johannes Schetelig, Christoph Schliemann, Sebastian Schwind, Matthias Stelljes, Leo F Verdonck, Vladan Vucinic, Bob Löwenberg, Jan Cornelissen

Haematologica 110(1) 68-77

PMID39113672
PMCIDPMC11694132
DOI10.3324/haematol.2024.285879
发表日期2024-08-08
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:已完成可用 Figure 的视觉复核,未识别到合格 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图。
摘要

摘要

Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed AML patients in CR1 aged 60-75 years were registered and a donor search initiated. After one consolidation cycle, patients with a matched donor were randomized to HCT with fludarabine/low-dose total body irradiation and cyclosporine/mycophenolate mofetil immunosuppression or conventional non-HCT. Primary outcome was restricted mean leukemia-free survival (RM-LFS) up to 5 years. Between 2010 and 2017, 245 patients (median age 67 years) were registered at CR1. After one consolidation, 26.9% of patients failed inclusion criteria. Of the 179 (73%) patients still on study, 75.4% had an HLA identical donor. Ten ineligible patients were excluded, and 125 randomized to HCT (N=83) or non-HCT (N=42). The primary outcome RM-LFS up to 5 years was 24.5 months (95% confidence interval [CI]: 18.9-30.1) in the HCT and 15.6 months (95% CI: 10.4-20.8) in the non-HCT arm (P=0.022) due to a decrease in cumulative relapse incidence from 91.1% (95% CI: 80.7-100.0) after non-HCT to 37.8% (95% CI: 27.2-48.4) after HCT (P<0.0001). The secondary endpoints RM-OS up to 5 years was 27.8 months (95% CI:22.3-33.2) in the HCT as compared to 28.6 months (95% CI: 22.2-35.0) in the non-HCT arm; non-relapse mortality at 5 years was 33.4% (95% CI: 23.0-43.9) with HCT and 0% without. In older patients with AML in CR1 5-year RM-LFS is better with HCT than with non-HCT consolidation treatment. The long-term RM-LFS benefit did not translate into a better RM-OS during the study period.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Flow chart. *Reason for dropout: 34 patients (morbidity, withdrawal of informed consent, no donor available, or unknown reasons), 26 no longer in first complete remission (CR1) (relapse, non-CR1, no hematological recovery) and 6 patients died. **Patients not receiving treatment according to randomization 20.5% (relapse N=7; morbidity N=4; withdrawal N=3; unavailable donor N=3). ***Patients not receiving treatment according to therapy as planned 16.7% (relapse N=2; morbidity N=2; withdrawal N=3). HCT: hematopoietic cell transplantation; CT: chemotherapy; Consol.: consolidation.
非 KM Figure
Figure 2.Outcome according to randomization to hematopoietic cell transplantation (HCT) or non-HCT analyzed following the intention to treat principles. Numbers below leukemia-free survival (LFS) and overall survival (OS) are number of patients at risk (number of patients censored). (A) LFS, (B) OS, (C) cumulative relapse incidence (RI) and (D) non-relapse mortality (NRM).
非 KM Figure